- Home
- PSNL vs TRVI Comparison
PSNL vs TRVI Comparison
Compare PSNL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | TRVI |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSNL | TRVI |
|---|---|---|
| Price | $15.77 | $14.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $15.17 | ★ $28.18 |
| AVG Volume (30 Days) | 2.2M | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $21.10 | N/A |
| Revenue Next Year | $30.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.96 | $9.82 |
| 52 Week High | $18.89 | $20.22 |
Technical Indicators
Market Signals| Indicator | PSNL | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 54.18 |
| Support Level | $15.51 | $13.08 |
| Resistance Level | $16.49 | $14.75 |
| Average True Range (ATR) | 0.25 | 0.73 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 28.69 | 79.38 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.